Tiffany Stevens

Physician at Expert Clinical Trial Advisor

[Toni Choueiri, MD @DrChoueiri]

The @ASCOPres Dr Eric Small…simply inspirational !

#ASCO2026

[gilberto lopes @GlopesMd]

#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq @narjustflorezmd @lungoncdoc @drshieldsmd @jackwestmd @n8pennell @mtmdphd @drarturoai @larvol @onclive @rmanochakian @devikadasmd @dryukselurun @dan_morgen @ptarantinomd
@DrJNaidoo @NaglaAKarimMD @Lung_Cancers @DrSanjayPopat @tnewsomdavis @Tony_Calles @ns_chd @BalazsHalmosMD @dr_yakupergun @ipreeshagul @FordePatrick @OncNewsCentral @imedverse @acmoorephd @DipeshUpretyMD @Alfdoc2 @g_mountzios @dmavicente @drshieldsmd @DrRiyazShah

[Chinmay Jani @Jani_Chinmay]

Having two of my mentors in the same frame! 😊 @GlopesMd @DrRanaMcKay

Grateful for their guidance, support, and the opportunities they continue to create for so many trainees. #ASCO26

[Dr. Estela Rodriguez @Latinamd]

#ASCO26 Up next @FSkoulidis @UTMDAnderson presents #Krascendo170 #Divarasib KRASG12C+IO combination ➡️in PDL1+ (n=59)
ORR 72.9%
➡️in PDL1 neg (n=23)
ORR 69.6%
⚠️ AEs- diarrhea, LFTs
#lcsm

👉🏽Here is a combination that may make a difference as a chemo-free option for high risk KRASG12C NSCLC w manageable toxicity @KRASKickers

[gilberto lopes @GlopesMd]

Alright - day 1 was a great start for #ASCO26. Here’s my #LCSM summary
6 trials that matter, in one thread

1️⃣ CROWN — 7-yr lorlatinib
2️⃣ AcceleRET-Lung — pralsetinib
3️⃣ Lunbotinib P2 — next-gen RET
4️⃣ OptiTROP-Lung05 — sac-TMT + pembro
5️⃣ WU-KONG28 — sunvozertinib
6️⃣ CHRYSALIS-2 — ami+laz, atypical EGFR

[Tiffany Stevens @TiffStevensMD]

#ASCO26 @mednewsweek @CParkMD @ASCO

[Dr. Estela Rodriguez @Latinamd]

The sexiest survival curve at #ASCO26 by far: updated 7-year PFS from the ITT population of #lorlatinib in the #CROWN trial for ALK+ #lungcancer, presented by @TonyMok9.

Longest duration of response yet seen with targeted therapy in #lungcancer: median PFS still not reached at 7 years.
55% vs 3% for crizotinib (HR 0.19).
➡️ looking forward to see what the next generation of ALK inhibitors will bring in terms of efficacy and improved toxicity profile

@ALKPositiveinc

[Tiffany Stevens @TiffStevensMD]

#ASCO26 @mednewsweek @CParkMD @ASCO

[Stephen V Liu, MD @StephenVLiu]

Dr. @FSkoulidis presents randomized phase 2b TRITON study at #ASCO26: chemo + durvalumab + tremelimumab vs chemo + pembro in non-squamous NSCLC with STK11, KEAP1, and/or KRAS mutations. RR numerically favors dual checkpoint in the challenging STK11 and KRAS subsets. PFS pending.

[Nancy Lin, MD @nlinmd]

Beautiful, moving remarks and call to action from Dr. Eric Small @ASCOPres. To all we have lost, family members and patients, we love you, we miss you, and it is our deepest privilege to honor your memory in the present.

[MJosé Juan @mjuanfi81]

TALAPRO-3: In HRR mHSPC, talazoparib+enzalutamide+ADT significantly improved rPFS vs enza+ADT (HR 0.48), 3yrPFS rates of 77% vs 56%. Greatest benefit in BRCA1/2 (HR 0.37) but also extended to non-BRCA HRR. Immature OS. Higher hematologic toxicity, particularly anemia
@OncoAlert

[Sara Coca Membribes @scocmem]

#ASCO26

1/2 ctDNA analysis (Signatera 16-plex and 64-plex) from KN564

Baseline ctDNA remained ⬇️(5.4% & 8.2%) yet ctDNA positivity consistently identified patients with worse DFS

ctDNA clearance was ⬆️with pembro & ctDNA dynamics correlated with DFS

@OncoAlert @DrChoueiri

[Vilma P. Barcia MD, PhD, MSc @DrVilmaPBarcia]

What a beautiful morning at #ASCO26. Ready for #OncoAlert5K!!! 🚀👏🏻
@OncoAlert @DraMartinezLago @weoncologists

[MOON LOVER @M1ONLOVER]

Full Moon

[Desomag @Desomag]

The Seven Sisters Waterfall, Geirangerfjord, Norway.

[Daniel Castellano @cdanicas]

🎯 #ASCO26 Kidney&Bladder Oral abstract session! @DrRanaMcKay RADICAL ph2 study in Bone mets of RCC with Cabo+/- Radium 223!
👉 similar outcomes between both arms (manageable toxicity and OS signal benefit🤷‍♂️🤷‍♂️) @OncoAlert @ASCO @ASCOPres @tompowles1 @DrChoueiri @apolo_andrea @neerajaiims

[Tom Powles @tompowles1]

Perioperative EV +pembo vs cystectomy (KN905) in MIBC shows great OS & pCR >50%. Quality of life data can be difficult to interpret due to multiple tools & different time points for analysis. Results did not show differences in the 2 arms at week 18 time point. Cystectomy had a more dramatic effect on QOL rather than EVP, but EVP will have both short term and long term side effects. While the methods used here are standard and well presented it feels there maybe a better way of assessing QOL. #ASCO26

[Nancy Lin, MD @nlinmd]

I wish Felix were still here to see all the incredible advances at ASCO this year. I miss his irrepressible energy so much. Let us support @ConquerCancerFd with a CDA to extend his legacy. Link below 👇

[𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD]

✅ The real power of #ASCO26?

Thousands of oncologists instantly sharing new data with the world on social media.

A practice-changing study can go from a Chicago podium to global discussion in hours.

Science moves fast. Oncology news moves faster.

Thank you to everyone for sharing cancer education for those that can’t be live at #ASCO26

Here are the Top 10 #ASCO26 influencers and impressions via @MedwatchKate

👉 https://t.co/UpKwv8l10x

@ASCO @OncoAlert @DrChoueiri @OncBrothers @GlopesMd @tompowles1 @montypal @urotoday @crisbergerot @weoncologists @PGrivasMDPhD @OncoReporte @realbowtiedoc @nataliagandur @StephenVLiu @imedverse

#Oncology #CancerResearch #CancerCare

[𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD]

#ASCO26 @asco @mednewsweek @CancerVisit_com @TiffStevensMD

[𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD]

#ASCO26 @asco @mednewsweek @CancerVisit_com @TiffStevensMD

[𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD]

#ASCO26 @asco @mednewsweek @CancerVisit_com @TiffStevensMD